ALK-Abelló
212.00 DKK
-1.12 %
Less than 1K followers
ALK B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-1.12 %
-6.28 %
-7.26 %
+2.81 %
+15.78 %
+36.33 %
+103.65 %
+51.97 %
+514.49 %
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen.
Read moreMarket cap
47.24B DKK
Turnover
17.81M DKK
Revenue
5.54B
EBIT %
19.7 %
P/E
57.61
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20.2
2026
Annual report '25
16.3
2026
General meeting '26
5.5
2026
Interim report Q1'26
All
Research
Webcasts
Press releases
ShowingAll content types
Invitation til præsentation af ALK’s årsrapport for 2025 fredag den 20. februar 2026
Dagens aktienyheder 30/01-2026: RTX, ALK og GreenMobility
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools








